No CYP-affinity. No conceivable effects on PXR activation. However, side effects such as nausea and vomiting may be potentially porphyrinogenic through reduction in caloric intake.

Trastuzumab is a recombinant DNA-derived humanized anti-HER2 monoclonal antibody.

Trastuzumab is an antineoplastic agent used in the treatment of breastcancer. It is administered as an intravenous infusion. Often administered together with paclitaxel, docetaxel or aromatase inhibitor e.g. anastrozol. Common adverse reactions of trastuzumab that can be confused with an acute porphyric attack are vomiting and nausea. Side effects such as nausea and vomiting may be potentially porphyrinogenic through reduction in caloric intake.

Metabolized as endogenous IgG. Non-CYP metabolism.

Used uneventfully for the treatment of breast cancer in AIP woman (Kristiansen, 2006).

No.